For instance, M2 TAMs release paracrine factors, CXCL1 and CXCL2, which enhance resistance to sorafenib (SOR) in advanced-stage hepatocellular carcinoma (HCC) cells. This evidence concerns the gene CXCL2 and hepatocellular carcinoma.